CYP19A1 and colorectal carcinoma: These results demonstrate that inhibition of CYP19A1 or complex I can effectively sensitize both chemoresistant and chemosensitive CRC cells to standard chemotherapeutic drugs, underscoring the potential broad applicability of targeting this pathway in colorectal cancer treatment.